8th European Conference on Rare Diseases & Orphan Products (ECRD 2016)
نویسندگان
چکیده
O1 The European Social Preferences Measurement (ESPM) study project: social cost value analysis, budget impact, commercial life cycle revenue management, and the economics of biopharmaceutical Research & Development (R&D) Michael Schlander, Søren Holm, Erik Nord, Jeff Richardson, Silvio Garattini, Peter Kolominsky-Rabas, Deborah Marshall, Ulf Persson, Maarten Postma, Steven Simoens, Oriol de Solà Morales, Keith Tolley, Mondher Toumi, Harry Telser Institute for Innovation & Valuation in Health Care (InnoVal-HC), An der Ringkirche 4, D-65197 Wiesbaden, Germany; Mannheim Medical Faculty, Institute of Public Health, University of Heidelberg, Ludolf-Krehl-Strasse 7-11, D-68167 Mannheim, Germany; University of Applied Economic Sciences, Ernst-Boehe-Strasse 4, D-67059 Ludwigshafen, Germany; Centre for Social Ethics and Policy, University of Manchester, Oxford Road, Manchester M13 9PL, UK; School of Pharmacy; University of Oslo, Sem Sælands vei 3 Farmasibygningen, N-0371 Oslo, Norway; Centre for Health Economics, Monash University; Clayton, Victoria 3800; Australia; IRCCS – Istituto di Richerche Farmacologiche Mario Negri, Via Giuseppe La Masa 19, I-20156 Milan, Italy; Interdisziplinäres Zentrum für Public Health (IZPH); Universitätsklinikum Erlangen, Schwabachanlage 6, D91054 Erlangen, Germany; Health Research Innovation Centre, Cumming School of Medicine, University of Calgary, 2500 University Dr. NW, Calgary, Alberta, T2N 1N4, Canada; The Swedish Institute for Health Economics (IHE), Box 2127, S-220 02 Lund, Sweden; Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1 9713 AV Groningen, The Netherlands, and Department of Epidemiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1 9713 GZ Groningen, The Netherlands; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Herestraat 49, B-3000 Leuven, Belgium; Institut Investigació Sanitaria Pere Virgili (IISPV), Avenir 1 Ppal 1a; E-08006 Barcelona; Tolley Health Economics Ltd, 19 Bath Road, Buxton, Derbyshire SK17 6HH, Great Britain; UFR d'Odontologie, University Claude Bernard Lyon I; 11 rue Guillaume Paradin; F-69372 Lyon Cedex 08, France; Polynomics AG, Baslerstrasse 44, CH-4600 Olten, Switzerland Correspondence: Michael Schlander ([email protected]; [email protected]; [email protected]) – University of Applied Economic Sciences, Ernst-Boehe-Strasse 4, D-67059 Ludwigshafen, Germany Orphanet Journal of Rare Diseases 2016, 11(Suppl 1):O1
منابع مشابه
Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen
BACKGROUND In the European Union (EU) and United States (US), specific regulations have been released to provide incentives to develop and sell orphan medicinal products. We analysed the status of orphan drugs designated that not yet received a marketing authorisation or already marketed for patients affected by rare diseases in the EU and US up to December 2015. For each drug, the following da...
متن کاملAre products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012
BACKGROUND Orphan designated medicinal products benefit from regulatory and economic incentives for orphan drug development. Approximately 40% of orphan designations target rare neoplastic disorders, referring to rare cancers. In order to provide more insights in drugs for rare neoplastic disorders that are under development and to better understand the role of orphan designation in the develop...
متن کاملState of the art of rare disease activities in Europe: a EUCERD perspective
Two years ago, at the ECRD in Krakow, we were celebrating the recommendation of the Council of Ministers on an action in the field of rare diseases: this recommendation requests that Member States define and implement a plan or a strategy for rare diseases by the end of 2013 and asks the European Commission to establish a EU Committee of Experts in the field of Rare Diseases (EUCERD) as a forum...
متن کاملState of the art of rare disease activities around the world: overview of the non-European landscape
With support from patient associations, political frameworks for rare diseases have been established throughout the world albeit with varying definitions for rare diseases. In the USA, the National Organization for Rare Disorders was instrumental in passing the 1983 Orphan Drug Act and the 2002 Rare Disease Act, which includes medical devices and dietary products as orphan products. In 2011, th...
متن کاملPharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007–13) and prospective (2014–18) MIDAS sales data analysis
BACKGROUND Health Canada has defined rare diseases as life-threatening, seriously debilitating, or serious chronic conditions affecting a very small number of patients (~1 in 2,000 persons). An estimated 9 % of Canadians suffer from a rare disease. Drugs treating rare diseases (DRDs) are also known as orphan drugs. While Canada is currently developing an orphan drug framework, in the United Sta...
متن کامل